Lung-specific sulfonium lipid nanoparticle formulation of dexamethasone suppresses endotoxin-induced lung inflammation
-
By
-
Yuqin Men
-
Chunyan Wang
-
David O. Popoola
-
Zhi Cao
-
Weikun Tian
-
Robert N. Cooney
-
Qinghe Meng
-
Yamin Li
-
May 29, 2026
-
Clinical Scorecard: Targeted Sulfonium Lipid Nanoparticle Delivery of Dexamethasone Reduces Endotoxin-Triggered Lung Inflammation
At a Glance
| Category | Detail |
|---|
| Condition | Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS) |
| Key Mechanisms | Lung-targeted delivery of dexamethasone using sulfonium lipid nanoparticles (sLNP) |
| Target Population | Patients with moderate-to-severe ARDS |
| Care Setting | Clinical settings involving acute respiratory failure |
Key Highlights
- Dex/DOSEH formulation significantly reduced proinflammatory cytokine production.
- Decreased immune cell infiltration and preserved capillary-alveolar barrier integrity.
- Attenuated histopathological lung injury in a murine model of ALI.
Guideline-Based Recommendations
Diagnosis
- Diagnosis of ALI/ARDS based on clinical criteria and imaging.
Management
- Consider intravenous administration of dexamethasone for moderate-to-severe ARDS.
Monitoring & Follow-up
- Monitor for adverse effects associated with systemic corticosteroid therapy.
Risks
- Adverse effects of systemic corticosteroids include hyperglycemia, infection susceptibility, gastrointestinal complications, and others.
Patient & Prescribing Data
Critically ill patients with ALI/ARDS.
Targeted delivery strategies may enhance efficacy and minimize off-target effects.
Clinical Best Practices
- Utilize targeted drug delivery systems to improve therapeutic outcomes in ALI/ARDS.
- Evaluate the risk-benefit ratio of corticosteroid therapy in critically ill patients.
Related Resources & Content
